Beijing Sun-Novo Pharmaceutical Research Balance Sheet Health
Financial Health criteria checks 5/6
Beijing Sun-Novo Pharmaceutical Research has a total shareholder equity of CN¥1.0B and total debt of CN¥535.7M, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are CN¥2.0B and CN¥979.5M respectively. Beijing Sun-Novo Pharmaceutical Research's EBIT is CN¥216.6M making its interest coverage ratio 44.6. It has cash and short-term investments of CN¥749.2M.
Key information
53.2%
Debt to equity ratio
CN¥535.68m
Debt
Interest coverage ratio | 44.6x |
Cash | CN¥749.17m |
Equity | CN¥1.01b |
Total liabilities | CN¥979.51m |
Total assets | CN¥1.99b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688621's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥841.1M).
Long Term Liabilities: 688621's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥138.4M).
Debt to Equity History and Analysis
Debt Level: 688621 has more cash than its total debt.
Reducing Debt: 688621's debt to equity ratio has increased from 6.9% to 53.2% over the past 5 years.
Debt Coverage: 688621's debt is well covered by operating cash flow (34%).
Interest Coverage: 688621's interest payments on its debt are well covered by EBIT (44.6x coverage).